JP2015091822A5 - - Google Patents

Download PDF

Info

Publication number
JP2015091822A5
JP2015091822A5 JP2014246066A JP2014246066A JP2015091822A5 JP 2015091822 A5 JP2015091822 A5 JP 2015091822A5 JP 2014246066 A JP2014246066 A JP 2014246066A JP 2014246066 A JP2014246066 A JP 2014246066A JP 2015091822 A5 JP2015091822 A5 JP 2015091822A5
Authority
JP
Japan
Prior art keywords
use according
excipient
sodium
final formulation
hpmc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014246066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015091822A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015091822A publication Critical patent/JP2015091822A/ja
Publication of JP2015091822A5 publication Critical patent/JP2015091822A5/ja
Pending legal-status Critical Current

Links

JP2014246066A 2007-10-12 2014-12-04 スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターを含む組成物 Pending JP2015091822A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97948207P 2007-10-12 2007-10-12
US60/979,482 2007-10-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010529013A Division JP6034000B2 (ja) 2007-10-12 2008-10-09 スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターを含む組成物

Publications (2)

Publication Number Publication Date
JP2015091822A JP2015091822A (ja) 2015-05-14
JP2015091822A5 true JP2015091822A5 (enExample) 2016-07-28

Family

ID=40032615

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010529013A Active JP6034000B2 (ja) 2007-10-12 2008-10-09 スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターを含む組成物
JP2014246066A Pending JP2015091822A (ja) 2007-10-12 2014-12-04 スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターを含む組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010529013A Active JP6034000B2 (ja) 2007-10-12 2008-10-09 スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターを含む組成物

Country Status (32)

Country Link
US (6) US8673918B2 (enExample)
EP (7) EP2653154A1 (enExample)
JP (2) JP6034000B2 (enExample)
KR (3) KR101600098B1 (enExample)
CN (1) CN101820916A (enExample)
AR (1) AR068986A1 (enExample)
AU (1) AU2008310846C1 (enExample)
BR (1) BRPI0818161B8 (enExample)
CA (2) CA2925175A1 (enExample)
CL (1) CL2008003003A1 (enExample)
CO (1) CO6270342A2 (enExample)
DK (1) DK2952177T3 (enExample)
EC (1) ECSP10010169A (enExample)
ES (2) ES2545361T3 (enExample)
HR (1) HRP20150838T1 (enExample)
HU (2) HUE027696T2 (enExample)
IL (3) IL204514B (enExample)
JO (2) JOP20080436B1 (enExample)
MA (1) MA31799B1 (enExample)
MX (1) MX337152B (enExample)
MY (1) MY159358A (enExample)
NZ (1) NZ600355A (enExample)
PE (2) PE20090799A1 (enExample)
PL (2) PL2952177T3 (enExample)
PT (2) PT2465492E (enExample)
RU (1) RU2010118457A (enExample)
SG (2) SG10201800085XA (enExample)
SI (2) SI2465492T1 (enExample)
TN (1) TN2010000136A1 (enExample)
TW (1) TW200927142A (enExample)
WO (1) WO2009048993A2 (enExample)
ZA (1) ZA201001819B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716448A1 (en) 2008-03-17 2009-09-24 Patrick Brossard Dosing regimen for a selective s1p1 receptor agonist
CA2733508A1 (en) * 2008-08-18 2010-02-25 David Leppert Compounds for the treatment of peripheral neuropathies
MX367667B (es) 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
US20100160259A1 (en) * 2008-12-22 2010-06-24 Robert Schmouder Dosage regimen for a s1p receptor agonist
EP2560621A1 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH Fingolimod in the form of a solid solution
US20130102683A1 (en) * 2010-04-22 2013-04-25 Ratiopharm Gmbh Melt-granulated fingolimod
CN101973898B (zh) * 2010-09-09 2013-06-19 南京明生医药技术有限公司 2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用
SG191286A1 (en) 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
ES2388273B1 (es) * 2011-03-16 2013-10-01 Consejo Superior De Investigaciones Científicas (Csic) Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
AR085749A1 (es) * 2011-04-01 2013-10-23 Novartis Ag Formulaciones
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
CA2852142A1 (en) * 2011-10-21 2013-04-25 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP2014129238A (ja) * 2012-12-28 2014-07-10 Lion Corp エトドラク含有固形製剤
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2996681B1 (en) * 2013-05-13 2019-12-18 Synthon B.V. Pharmaceutical composition comprising fingolimod
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
US20150141520A1 (en) * 2013-11-18 2015-05-21 Chandrasekhar Kandi Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
KR102466348B1 (ko) * 2014-04-10 2022-11-10 노파르티스 아게 면역억제제 제제
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US20170231928A1 (en) * 2014-08-22 2017-08-17 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
RU2017112748A (ru) * 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
WO2016118515A1 (en) 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
EP3290037A4 (en) * 2015-04-28 2019-01-23 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
DK3334709T3 (da) 2015-08-12 2025-02-03 Incyte Holdings Corp Salte af en lsd1-hæmmer
RU2639424C2 (ru) * 2015-09-15 2017-12-21 Закрытое Акционерное Общество "Биокад" Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза
WO2017058364A1 (en) * 2015-10-02 2017-04-06 Mylan Inc. Stable formulations of fingolimod
CA3021678A1 (en) * 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
CA3105187A1 (en) 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020071539A1 (ja) 2018-10-05 2020-04-09 富士化学工業株式会社 多孔性シリカ粒子組成物
KR102885760B1 (ko) * 2021-04-14 2025-11-13 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제를 포함하는 고형 제제의 제조 방법
CN117202893A (zh) * 2021-04-14 2023-12-08 株式会社Lg化学 包含鞘氨醇-1-磷酸受体激动剂的可直接压缩的药物组合物
CN117120037A (zh) * 2021-04-14 2023-11-24 株式会社Lg化学 包含具有受控粒度的鞘氨醇-1-磷酸酯受体激动剂的药物组合物
US20260207513A1 (en) 2022-12-12 2026-07-23 Synthon B.V. Pharmaceutical composition of siponimod

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
WO1997024112A1 (en) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
EP2030614A1 (en) 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
ES2240868T3 (es) 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
CZ200350A3 (cs) 2000-07-13 2003-05-14 Sankyo Company Limited Aminoalkoholové deriváty
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
JP4152884B2 (ja) 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
KR100913269B1 (ko) 2001-09-27 2009-08-21 교린 세이야꾸 가부시키 가이샤 디아릴 황화물 유도체, 그의 염 및 이를 이용한 면역억제제
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
JP4571497B2 (ja) 2002-09-19 2010-10-27 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
DK1602660T3 (da) 2003-02-18 2011-05-23 Kyorin Seiyaku Kk Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer
CA2707750A1 (en) * 2003-04-08 2004-10-21 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
FR2854549B1 (fr) 2003-05-06 2005-06-24 Actis Ets Tete pour l'equipement d'un bras de robot destine a realiser une operation d'ebavurage ou de cardage
EP1628967B1 (en) 2003-05-19 2014-04-09 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US7838562B2 (en) 2003-06-24 2010-11-23 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
EP1660449B1 (en) 2003-08-28 2009-11-18 Novartis AG Aminopropanol derivatives
WO2005025553A2 (en) * 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
US8633161B2 (en) 2005-03-24 2014-01-21 The Ohio State University Research Foundation Therapeutic agents for the treatment of leukemia
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
RU2487703C2 (ru) 2006-09-26 2013-07-20 Новартис Аг Фармацевтические композиции, включающие модулятор s1р

Similar Documents

Publication Publication Date Title
JP2011500583A5 (enExample)
RU2010118457A (ru) Композиции, содержащие модуляторы рецептора сфингозин-1-фосфата (sip)
US8512751B2 (en) Pharmaceutical compositions for sleep disorders
RU2016144479A (ru) Фармацевтические композиции для лечения заболеваний, опосредопосредованных муковисцидозным трансмембранным регулятором проводимости
CN106456583B (zh) 用于治疗神经障碍的巴氯芬、阿坎酸和中链甘油三酯的组合
CA2691208A1 (en) Combination therapy for depression
JP2014520842A (ja) モンテルカストおよびリボセチリジン配合のカプセル製剤
JP2015510916A5 (enExample)
JP2022545156A5 (enExample)
JP2021152060A (ja) アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法
JP5941258B2 (ja) 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール
JP2019218379A5 (enExample)
JP2009040767A5 (enExample)
JP2021512869A5 (enExample)
JP6181044B2 (ja) カプセル剤
JP2023502738A5 (enExample)
WO2024139978A1 (zh) Vofopitant用于治疗肺纤维化的用途
JP2016537344A5 (enExample)
RU2021123106A (ru) Композиции, содержащие модуляторы рецептора сфингозин-1-фосфата (s1p)
TW200920348A (en) Combination of picotamide with nafronyl
WO2013180675A1 (en) Tablet formulation comprising dapoxetine
ES2952013T3 (es) Combinación de ibuprofeno y tramadol para aliviar el dolor
JP6227352B2 (ja) アナグリプチン又はその塩を含有する固形製剤
TH103571A (th) องค์ประกอบซึ่งประกอบด้วยตัวปรับสฟิงโกชีน 1 ฟอสเฟด (s1p) รีเซพเตอร์
AU2018258970B2 (en) Idalopirdine-based combinatorial therapies of Alzheimer's disease